Lenalidomide has demonstrated single-agent ... specifically neutropenia and thrombocytopenia. Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

Follicular lymphoma usually appears as painless ... Such combinations include an immunomodulatory agent (lenalidomide), a checkpoint inhibitor (atezolizumab), a Bcl2 inhibitor (venetoclax ...

The pairing of Revlimid (lenalidomide) and Rituxan (rituximab) – known as the R 2 regimen – has been cleared for patients with previously-treated follicular lymphoma (FL) and marginal zone ...